论文部分内容阅读
目的观察12-氧-十四烷酰佛波醇-13-乙酸酯(TPA)联合伊马替尼治疗伊马替尼耐药的慢性粒细胞白血病(CML)急变期患者的临床疗效。方法选择常规剂量伊马替尼耐药的CML急性期患者12例,应用TPA联合伊马替尼治疗,观察其血液学缓解率、细胞遗传学缓解率和长期生存率。结果12例患者中11例可进行临床疗效评价,其中完全血液学缓解率36.36%(4/11),部分血液学缓解率36.36%(4/11),总的血液学缓解率达72.72%(8/11);完全细胞遗传学缓解率18.18%(2/11),部分细胞遗传学缓解率45.45%(5/11),总的细胞遗传学缓解率达63.64%(7/11)。结论TPA联合伊马替尼治疗常规剂量伊马替尼耐药的CML急变期患者是可行的。
Objective To investigate the clinical efficacy of 12-oxo-tetradecanoylphorbol-13-acetate (TPA) combined with imatinib in the treatment of imatinib-resistant chronic myeloid leukemia (CML) patients. Methods Twelve patients with conventional CML-resistant acute myeloid leukemia (CML) were selected and treated with TPA combined with imatinib. Hematological response rate, cytogenetic response rate and long-term survival rate were observed. Results Of the 12 patients, 11 cases were evaluated for clinical efficacy. The complete hematological response rate was 36.36% (4/11), partial hematological response rate was 36.36% (4/11), and the total hematologic response rate was 72.72% The complete cytogenetic response rate was 18.18% (2/11), partial cytogenetic response rate was 45.45% (5/11), and the total cytogenetic response rate was 63.64% (7/11). Conclusion It is feasible that TPA plus imatinib is effective in treating CML patients with conventional dose of imatinib-resistant CML.